Evidence map›Paper›PMID 36362704›Full record

ArticleJournal of clinical medicine2022

Proactive versus Rank-Down Topical Corticosteroid Therapy for Maintenance of Remission in Pediatric Atopic Dermatitis: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study (Anticipate Study).

Koji Kamiya, Hidehisa Saeki, Yoshiki Tokura, Shigemi Yoshihara, Junichi Sugai, Mamitaro Ohtsuki

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Topical anti-inflammatory treatments for eczema: network meta-analysis.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Review
  3. Long-term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026
    Article
  4. Topical proactive therapy in dermatology. A scoping review.Postepy dermatologii i alergologii · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Koji KamiyaDepartment of Dermatology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Tochigi, Japan.ORCID 0000-0002-7938-1947
Hidehisa SaekiDepartment of Dermatology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku 113-8602, Tokyo, Japan.
Yoshiki TokuraAllergic Disease Research Center and Department of Dermatology & Skin Oncology, Chutoen General Medical Center, 1-1 Shobugaike, Kakegawa 436-8555, Shizuoka, Japan.ORCID 0000-0001-7452-6919
Shigemi YoshiharaDepartment of Pediatrics, Dokkyo Medical University, 880 Kitakobayashi, Mibu 321-0293, Shimotsuga, Tochigi, Japan.
Junichi SugaiSugai Dermatology Parkside Clinic, 6-7-7 Motoimaizumi, Utsunomiya 321-0954, Tochigi, Japan.
Mamitaro OhtsukiDepartment of Dermatology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Tochigi, Japan.
Jichi Medical University · JPDokkyo Medical University · JPNippon Medical School · JP

Funding

Torii Pharmaceutical Co., Ltd. Unnumbered
6 · The paper itself

Abstract

Topical corticosteroids are used as first-line treatment for atopic dermatitis (AD). Regarding the maintenance of remission achieved by topical corticosteroids, no previous studies have compared proactive therapy with rank-down therapy. We compared their efficacy and safety in Japanese children with moderate to severe AD. Patients who had achieved remission with a very strong topical corticosteroid were randomized to 4-week maintenance treatment with either intermittent use of the same drug (proactive therapy) or daily use of a strong topical corticosteroid for 1 week followed by daily use of a medium-potency topical corticosteroid for 3 weeks (rank-down therapy); 49 patients were randomized (proactive therapy,

Indexed as

atopic dermatitispediatricproactive therapyrank-down therapytopical corticosteroids

Identifiers

PMID36362704
PMCPMC9658234
OpenAlexW4308127637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.